Deep Track discloses 6.78% Enanta (ENTA) stake in Schedule 13G/A

Rhea-AI Filing Summary

Deep Track Capital and affiliates report a 6.78% stake in Enanta Pharmaceuticals Inc. The group, including Deep Track Biotechnology Master Fund and David Kroin, beneficially owns 1,956,867 shares of Enanta common stock, with shared voting and dispositive power over all reported shares.

The ownership percentage is based on 28,862,601 Enanta common shares outstanding as of November 4, 2025, as referenced from the company’s Form 10-K. The reporting persons certify the shares are not held for the purpose of changing or influencing control of Enanta.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ENANTA PHARMACEUTICALS INC

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

29251M106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 29251M106

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,956,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,956,867.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,956,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.78 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 29251M106

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,956,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,956,867.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,956,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.78 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 29251M106

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,956,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,956,867.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,956,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.78 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENANTA PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 4 KINGSBURY AVENUE, WATERTOWN, MA, 02472
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, par value $0.01 per share
(e)	CUSIP No.: 29251M106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,956,867
(b)	Percent of class: 6.78%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,956,867
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,956,867
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	02/13/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	02/13/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	02/13/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 28,862,601 Common Stock outstanding as of November 4, 2025, according to the issuer's 10-K filed with the SEC on November 19, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 13, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

What percentage of Enanta Pharmaceuticals (ENTA) does Deep Track Capital own?

Deep Track Capital and related reporting persons beneficially own 6.78% of Enanta Pharmaceuticals’ common stock. This corresponds to 1,956,867 shares, calculated against 28,862,601 shares outstanding as of November 4, 2025, according to Enanta’s Form 10-K filed on November 19, 2025.

How many Enanta (ENTA) shares are reported as beneficially owned in this Schedule 13G/A?

The filing reports beneficial ownership of 1,956,867 Enanta common shares. All of these shares are subject to shared voting and shared dispositive power, with no sole voting or sole dispositive authority reported by Deep Track Capital, its master fund, or David Kroin.

Who are the reporting persons in the Enanta (ENTA) Schedule 13G/A filing?

The reporting persons are Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. Each reports beneficial ownership of the same 1,956,867 Enanta common shares and discloses shared voting and shared dispositive power over these securities.

Is Deep Track’s Enanta (ENTA) stake intended to influence control of the company?

The reporting persons certify the Enanta shares were not acquired and are not held to change or influence control of the issuer. They also state the holdings are not part of any transaction with that purpose, other than activities solely in connection with a nomination under Rule 240.14a-11.

How was Deep Track’s ownership percentage in Enanta (ENTA) calculated?

The 6.78% ownership figure is based on 28,862,601 Enanta common shares outstanding as of November 4, 2025. That share count comes from Enanta’s Form 10-K filed on November 19, 2025, and is used to compute Deep Track’s percentage for this Schedule 13G/A.

What voting and dispositive powers are reported over Enanta (ENTA) shares?

The filing shows zero sole voting or sole dispositive power and 1,956,867 shares with shared voting and shared dispositive power. This means decisions to vote or dispose of the Enanta shares are made jointly among the reporting persons rather than individually.